ExoVerita Pro
Commercial- Indications
- Research use only
Company intelligence / Profile preview
Biological Dynamics has developed the ExoVerita Pro platform using proprietary ACE technology to rapidly isolate exosomes from blood and other biofluids. This enables highly sensitive early-stage cancer detection—e.g., identifying up to 71% of stage I cancers in one study cohort, including up to 96% of pancreatic cancers detected. The company’s focus remains on deploying this diagnostic tool across multiple clinical settings for earlier intervention and improved outcomes.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Biological Dynamics.